Luminex Says Q2 xTAG GPP Sales 'Strongest to Date,' Calls BioFire Gastro Test Market Entry a 'Net Positive' | GenomeWeb

NEW YORK (GenomeWeb) – Demand for Luminex'sxTAG Gastrointestinal Pathogen Panel continues to increase despite the US Food and Drug Administration's recent clearance of a competitive assay sold by BioMérieux.

In fact, the Austin, Texas-based molecular diagnostics company experienced its greatest amount of GPP sales since the FDA cleared the test early last year, and believes BioMérieux's offering will help to grow the market for multiplex gastrointestinal pathogen testing, rather than siphon off sales, according to Luminex CEO Patrick Balthrop.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.